Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002455|
Recruitment Status : Unknown
Verified November 1998 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : January 27, 2003
Last Update Posted : August 7, 2013
RATIONALE: Immunotherapy uses different ways to stimulate the immune system and stop cancer cells from growing. Immunotherapy biological extracts may be useful as adjuvant therapy in treating patients who have had surgery for breast cancer, colon cancer, or melanoma.
PURPOSE: Phase III trial to study the effectiveness of Corynebacterium granulosum extract as maintenance immunotherapy following surgery in treating patients with breast cancer, colon cancer, or melanoma.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Colorectal Cancer Melanoma (Skin)||Biological: Corynebacterium granulosum P40 Procedure: adjuvant therapy||Phase 3|
- Determine the survival of patients with colon cancer, breast cancer, or melanoma with minimal residual disease after surgical resection treated with maintenance immunotherapy using Corynebacterium granulosum P40.
- Determine leucocyte adherence inhibition, an indication of metastases, over time in patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified by center and are matched with case-controls by disease type and stage.
Beginning 2 weeks after surgical resection, patients receive Corynebacterium granulosum P40 subcutaneously weekly for 6 weeks, followed by rest for 3 months. Treatment continues for life.
Patients are followed for survival.
PROJECTED ACCRUAL: Not specified
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts|
|Study Start Date :||April 1971|
- Response to study parameters
- Survival rate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002455
|Centro Oncologico de Excelencia|
|Gonnet, Buenos Aires, Argentina, 1987 MB|
|Study Chair:||Hugo Omar De Carli, MD||Centro Oncologico de Excelencia|